TL;DR
This study investigated whether prior HIV envelope vaccination influences the antibody response after breakthrough HIV infection. Researchers found that existing envelope-based vaccines did not significantly alter the binding or neutralizing antibody responses post-infection, nor did they accelerate the development of broad neutralization. This suggests that current vaccine strategies may need to focus on eliciting different types of immune responses to achieve effective protection.
What Problem Does This Paper Address?
Developing an effective HIV vaccine remains a critical global health challenge. While many studies have characterized the immune responses induced by experimental HIV vaccines in uninfected individuals, there's a significant knowledge gap regarding how these pre-existing vaccine-induced responses behave after an individual becomes infected with HIV. Understanding this is crucial because breakthrough infections, though undesirable, offer a unique opportunity to study how the immune system interacts with both the vaccine and the actual virus. Specifically, researchers wanted to know if prior vaccination could "prime" the immune system in a way that leads to a more robust or broader antibody response upon natural infection, potentially offering some level of control or insight into vaccine design.
Methods
The study employed standard immunological assays to measure antibody responses. Serum samples from participants who acquired HIV infection after being enrolled in HIV vaccine trials were collected longitudinally (annually for up to 6 years post-infection).
- Binding Antibody Assays: Enzyme-linked immunosorbent assays (ELISA) and a binding antibody multiplex assay (BAMA) were used to detect and quantify antibodies that bind to various HIV envelope proteins and peptides (including gp41, V3, V2, membrane-proximal external region (MPER), and CD4 binding site).
- Neutralization Assays: The TZM-bl cell neutralization assay was used to assess the ability of antibodies to neutralize HIV. This involved measuring the reduction in luciferase gene expression after infection with pseudotyped viruses. They tested neutralization against "tier 1A" viruses (easier to neutralize) and a panel of "tier 2" viruses (more difficult to neutralize and considered more relevant for broad neutralization).
Datasets
The study utilized serum samples from participants in three specific HIV vaccine trials conducted in South Africa:
- HVTN 073: Phase 1 trial of a DNA/MVA vaccine (n=1 infected participant).
- HVTN 086: Phase 1 trial of a DNA/MVA/gp140 protein vaccine (n=2 infected participants).
- HVTN 204: Phase 2 trial of a DNA/adenovirus serotype 5 (Ad5) vaccine (n=7 infected participants).
Additionally, serum samples from 4 placebo recipients from these trials who also acquired HIV infection were included. Unvaccinated HIV-infected individuals from the CAPRISA cohort served as a control group for comparison of neutralization breadth.
Key Insights and Ideas
- Waning of Vaccine Immunity: Antibody responses elicited by the vaccines had largely waned by the time of HIV infection, as no significant responses were detected just prior to infection. This highlights the transient nature of some vaccine-induced antibody responses.
- HIV Infection as the Primary Stimulus: The development of HIV-specific antibody responses post-infection appeared to be primarily driven by the natural infection itself, rather than being significantly boosted by pre-existing vaccine-induced memory. The kinetics and levels of antibody responses were similar between vaccinated and placebo groups.
- Lack of Priming for Broad Neutralization: The tested envelope-containing vaccines did not prime the immune system to develop tier 2 virus-neutralizing antibodies or accelerate the development of neutralization breadth, which are considered crucial for effective HIV prevention.
- No Negative Impact: A significant finding is that prior vaccination did not appear to have a negative impact on the immune response to HIV infection. This is an important observation for future vaccine development.
Key Results
- Binding Antibodies: HIV-specific binding antibodies to gp41, V3, V2, MPER, and the CD4 binding site were detected within the first year of infection. These levels were similar in both vaccinated and placebo recipients and persisted for at least 3 years.
- Tier 1A Neutralization: Neutralizing antibodies against tier 1A viruses were detected in all participants post-infection, with the highest titers against a subtype C virus (MW965.26). There were no significant differences in these responses between vaccinated and placebo groups.
- Tier 2 Neutralization: Sporadic and weak neutralization activity against tier 2 viruses was observed in some participants after 2-3 years of infection. However, these responses were similar across vaccinated, placebo, and unvaccinated control groups, indicating no significant priming effect.
- Neutralization Breadth: Only a small proportion of participants (both vaccinated and unvaccinated) developed neutralization breadth (defined as neutralizing 5 or more viruses). Prior vaccination did not accelerate this development.
Limitations and Future Work
- Small Sample Size: The study involved a limited number of participants (14 infected vaccine recipients and 4 placebo recipients), which may have restricted the ability to detect subtle differences.
- Varied Vaccine Regimens: Participants received different vaccine regimens (DNA, MVA, Ad5, protein boosts), which likely resulted in varying levels of antigen exposure and antibody responses, making direct comparisons complex.
- Time to Infection: A gap of up to one year between estimated infection dates and diagnosis dates could have influenced the measurements.
- Antigenic Overlap: The study suggests that the B-cell lineages induced by the vaccines might not overlap with those activated by natural HIV infection, which would require further investigation into B-cell receptor repertoires.
The authors suggest that future work should focus on testing newer immunogens that can stimulate B-cell lineages capable of maturing into broadly neutralizing antibodies, potentially through germline-targeting vaccines or trimeric envelope glycoproteins. They also highlight the need for larger efficacy trials with more available samples from vaccinated and infected individuals to expand this type of analysis.
Summary updated